DiaMedica Therapeutics Inc. Common Stock/DMAC

$3.19

3.91%
-
1D1W1MYTD1YMAX

About DiaMedica Therapeutics Inc. Common Stock

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company's lead product, DM199, is an active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein for the treatment of AIS and CKD, including hypertensive nephrosclerosis (hypertension). KLK1 is a serine protease (protein) that plays a role in the regulation of diverse physiological processes, including blood flow, inflammation, fibrosis, oxidative stress, and neurogenesis, via a molecular mechanism that increases the production of nitric oxide and prostaglandin. It has also identified a potential treatment for inflammatory diseases, DM300, which is in the early preclinical stage of development.

Ticker

DMAC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Rick Pauls

Employees

16

Headquarters

Minneapolis, United States

DMAC Metrics

BasicAdvanced
$116.52M
Market cap
-
P/E ratio
-$0.62
EPS
1.70
Beta
-
Dividend rate

What the Analysts think about DMAC

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
161.13% upside
High $11.00
Low $7.00
$3.19
Current price
$8.33
Average price target

DMAC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-4.4M
-0%
Profit margin
0%
-

DMAC Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.26%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.14
-$0.20
-$0.16
-$0.12
-
Expected
-$0.14
-$0.16
-$0.18
-$0.13
-$0.14
Surprise
0%
25%
-9.43%
-5.26%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell DiaMedica Therapeutics Inc. Common Stock stock

Buy or sell DiaMedica Therapeutics Inc. Common Stock stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing